Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.63 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.63 |
| ▸ | ACP1 | P24666 | 7/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101655 | 0.94 | ABCG2 (0.53) | ABCG2ABCB1ABCC1ACP1CYP3A4 | |
| SCHEMBL4914944 | 0.90 | IGF1R (0.53) | ABCG2ABCB1ABCC1ACP1CYP3A4 | |
| SCHEMBL4909868 | 0.85 | CYP3A4 (0.48) | ABCG2ABCB1ABCC1ACP1CYP3A4 | |
| SCHEMBL4915694 | 0.85 | IGF1R (0.53) | ACP1CNR1MAPTHTTNPSR1 | |
| SCHEMBL4911277 | 0.85 | IGF1R (0.60) | ACP1CNR1CYP3A4MAPTMOK | |
| SCHEMBL4912729 | 0.84 | IGF1R (0.47) | ABCG2ABCB1ABCC1CNR1CYP3A4 | |
| SCHEMBL4909854 | 0.84 | MEN1 (0.50) | ABCG2ABCB1ABCC1ACP1CNR1 | |
| SCHEMBL4910112 | 0.84 | ABCG2 (0.47) | ABCG2ABCB1ABCC1ACP1CNR1 | |
| SCHEMBL4912812 | 0.84 | KMT2A (0.49) | ACP1CYP3A4MOKMEN1KMT2A | |
| SCHEMBL4911258 | 0.84 | CYP3A4 (0.52) | ACP1CYP3A4MOKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-9193687-B2 | Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents | ACADEMIA SINICA (TW) | 2015-11-24 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | ACADEMIA SINICA (TW) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178494-A1 | PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS | PCNA, WEE1, UNG | ABCG2 136/4885ABCB1 315/4885ABCC1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.